Foster R - Search Results

1

Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau.

Starbuck K, Al-Alem L, Eavarone DA, Hernandez SF, Bellio C, Prendergast JM, Stein J, Dransfield DT, Zarrella B, Growdon WB, Behrens J, Foster R, Rueda BR. Starbuck K, et al. Among authors: foster r. Oncotarget. 2018 May 1;9(33):23289-23305. doi: 10.18632/oncotarget.25289. eCollection 2018 May 1. Oncotarget. 2018. PMID: 29796189 Free PMC article.

2

Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer.

Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR. Curley MD, et al. Among authors: foster r. Front Biosci (Landmark Ed). 2011 Jan 1;16(1):368-92. doi: 10.2741/3693. Front Biosci (Landmark Ed). 2011. PMID: 21196176 Free article. Review.

3

Ovarian cancer stem cells: working towards the root of stemness.

Foster R, Buckanovich RJ, Rueda BR. Foster R, et al. Cancer Lett. 2013 Sep 10;338(1):147-57. doi: 10.1016/j.canlet.2012.10.023. Epub 2012 Nov 5. Cancer Lett. 2013. PMID: 23138176 Review.

4

Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo.

Kulkarni-Datar K, Orsulic S, Foster R, Rueda BR. Kulkarni-Datar K, et al. Among authors: foster r. Cancer Lett. 2013 Oct 10;339(2):237-46. doi: 10.1016/j.canlet.2013.06.014. Epub 2013 Jun 18. Cancer Lett. 2013. PMID: 23791886

5

Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.

Bradford LS, Rauh-Hain A, Clark RM, Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R, Rueda BR. Bradford LS, et al. Among authors: foster r. Gynecol Oncol. 2014 May;133(2):346-52. doi: 10.1016/j.ygyno.2014.02.022. Epub 2014 Feb 19. Gynecol Oncol. 2014. PMID: 24561032

6

Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth.

Groeneweg JW, DiGloria CM, Yuan J, Richardson WS, Growdon WB, Sathyanarayanan S, Foster R, Rueda BR. Groeneweg JW, et al. Among authors: foster r. Front Oncol. 2014 Jul 7;4:171. doi: 10.3389/fonc.2014.00171. eCollection 2014. Front Oncol. 2014. PMID: 25072022 Free PMC article.

7

Notch signaling in serous ovarian cancer.

Groeneweg JW, Foster R, Growdon WB, Verheijen RH, Rueda BR. Groeneweg JW, et al. Among authors: foster r. J Ovarian Res. 2014 Nov 4;7:95. doi: 10.1186/s13048-014-0095-1. J Ovarian Res. 2014. PMID: 25366565 Free PMC article. Review.

8

The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.

Diver EJ, Foster R, Rueda BR, Growdon WB. Diver EJ, et al. Among authors: foster r. Oncologist. 2015 Sep;20(9):1058-68. doi: 10.1634/theoncologist.2015-0149. Epub 2015 Jun 22. Oncologist. 2015. PMID: 26099744 Free PMC article. Review.

9

Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.

Hernandez SF, Chisholm S, Borger D, Foster R, Rueda BR, Growdon WB. Hernandez SF, et al. Among authors: foster r. Gynecol Oncol. 2016 Jun;141(3):570-579. doi: 10.1016/j.ygyno.2016.03.027. Epub 2016 Apr 1. Gynecol Oncol. 2016. PMID: 27017985

10

Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.

Garrett LA, Growdon WB, Rueda BR, Foster R. Garrett LA, et al. Among authors: foster r. J Ovarian Res. 2016 Sep 15;9(1):58. doi: 10.1186/s13048-016-0267-2. J Ovarian Res. 2016. PMID: 27633667 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,379 results

Search Page